Expert Review of Anti-infective Therapy最新文献_第2页

From tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF): perspectives in pediatric patients. 从富马酸替诺福韦二吡呋酯（TDF）到替诺福韦阿拉非酰胺（TAF）：儿科患者的视角。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-10-03 DOI: 10.1080/14787210.2024.2412991

Minna Rodrigo, Christopher Hartley, Trung Van, Paul Wasuwanich, Wikrom Karnsakul

{"title":"From tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF): perspectives in pediatric patients.","authors":"Minna Rodrigo, Christopher Hartley, Trung Van, Paul Wasuwanich, Wikrom Karnsakul","doi":"10.1080/14787210.2024.2412991","DOIUrl":"https://doi.org/10.1080/14787210.2024.2412991","url":null,"abstract":"Introduction: Hepatitis B virus (HBV) affects hundreds of millions globally, with many cases stemming from perinatal transmission. Chronic hepatitis B (CHB) in children can progress to cirrhosis and hepatocellular carcinoma (HCC) in adulthood. Treatment options include interferons and nucleos(t)ide reverse transcriptase inhibitors (N[t]RTIs) such as tenofovir alafenamide (TAF).Areas covered: This review covers the epidemiology of pediatric CHB and current treatments, with a focus on tenofovir-based therapies, particularly tenofovir disoproxil fumarate (TDF) and TAF. TDF has been used for years, but its risks of bone mineral density loss and renal impairment have raised concerns. TAF, with lower systemic exposure, appears to mitigate these risks. Ongoing trials are evaluating TAF's safety in younger children. There are knowledge gaps in long-term safety and the potential for combination therapies.Expert opinion: TAF offers a safer alternative to TDF for children with CHB, showing high antiviral efficacy and fewer side effects. However, more data is needed on its use in younger children and long-term safety. The future of CHB treatment in pediatrics may include combination therapies and personalized approaches, potentially improving outcomes and minimizing risks over a lifetime of treatment. As research progresses, TAF is likely to become a cornerstone in pediatric CHB management.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142364959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New and emerging roles for inhalational and direct antifungal drug delivery approaches for treatment of invasive fungal infections. 吸入式和直接抗真菌给药方法在治疗侵袭性真菌感染方面的新作用。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-09-29 DOI: 10.1080/14787210.2024.2409408

Chin Fen Neoh, Wirawan Jeong, David C M Kong, Justin Beardsley, Philip Chi Lip Kwok, Monica A Slavin, Sharon C-A Chen

{"title":"New and emerging roles for inhalational and direct antifungal drug delivery approaches for treatment of invasive fungal infections.","authors":"Chin Fen Neoh, Wirawan Jeong, David C M Kong, Justin Beardsley, Philip Chi Lip Kwok, Monica A Slavin, Sharon C-A Chen","doi":"10.1080/14787210.2024.2409408","DOIUrl":"https://doi.org/10.1080/14787210.2024.2409408","url":null,"abstract":"Introduction: The rising prevalence of difficult-to-treat, deep-seated invasive fungal diseases (IFD) has led to high mortality. Currently available antifungal treatments, administered predominantly orally or intravenously, may not sufficiently penetrate certain body sites, and/or are associated with systemic toxicity. Little is known about how to position alternative administration approaches such as inhalational and direct drug delivery routes.Areas covered: This review provides an updated overview of unconventional drug delivery strategies for managing IFD, focusing on inhalational (to target the lungs) and direct delivery methods to the central nervous system, bone/joint, and eyes. Novel compounds (e.g. opelconazole) and existing antifungals with innovative drug delivery systems currently undergoing clinical trials and/or used off-label in the clinical setting are discussed.Expert opinion: For both inhalational agents and direct delivery approaches, there are similar challenges that include the absence of: approved formulations for specific administration routes, delivery vehicles that are simple and safe to use whilst maintaining potency and efficiency of delivery, animal models suitable for investigating pharmacokinetic/pharmacodynamic profiles of inhaled antifungals, and consensus on the composite endpoints and intervals for of follow-up in clinical trials. To meet these challenges, cooperation of all stakeholders in drug development and regulation is required.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-14"},"PeriodicalIF":4.2,"publicationDate":"2024-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent updates in treating carbapenem-resistant infections in patients with hematological malignancies. 治疗血液恶性肿瘤患者耐碳青霉烯类感染的最新进展。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-09-29 DOI: 10.1080/14787210.2024.2408746

Abdullah Tarık Aslan, Murat Akova

{"title":"Recent updates in treating carbapenem-resistant infections in patients with hematological malignancies.","authors":"Abdullah Tarık Aslan, Murat Akova","doi":"10.1080/14787210.2024.2408746","DOIUrl":"10.1080/14787210.2024.2408746","url":null,"abstract":"Introduction: Patients with hematological malignancies (PHMs) are at increased risk for infections caused by carbapenem-resistant organisms (CROs) due to frequent exposure to broad-spectrum antibiotics and prolonged hospital stays. These infections result in high mortality and morbidity rates along with delays in chemotherapy, longer hospitalizations, and increased health care costs.Areas covered: Treatment alternatives for CRO infections in PHMs.Expert opinion: The best available treatment option for KPC and OXA-48 producers is ceftazidime/avibactam. Imipenem/cilastatin/relebactam and meropenem/vaborbactam remain as the alternative options. They can also be used as salvage therapy in KPC-positive Enterobacterales infections resistant to ceftazidime/avibactam, if in vitro susceptibility is shown. Treatment of metallo-β-lactamase producers is an unmet need. Ceftazidime/avibactam plus aztreonam or aztreonam/avibactam seems to be the most reliable option for metallo-β-lactamase producers. As a first-line option for carbapenem-resistant Pseudomonas aeruginosa infections, ceftolozane/tazobactam is preferable and ceftazidime/avibactam and imipenem/cilastatin/relebactam constitute alternative regimens. Although sulbactam/durlobactam is the most reliable option against carbapenem-resistant Acinetobacter baumannii infections, its utility as monotherapy and in PHMs is not yet known. Cefiderocol can be selected as a 'last-resort' option for CRO infections. New risk score models supported by artificial intelligence algorithms can be used to predict the exact risk of infections in previously colonized patients.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-17"},"PeriodicalIF":4.2,"publicationDate":"2024-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142307461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ceftolozane/Tazobactam treatment for patients with hospital-acquired and ventilatory-associated bacterial pneumonia in Canada in 2022-2024: results from the CLEAR registry. 2022-2024 年加拿大医院获得性和呼吸机相关细菌性肺炎患者的头孢唑烷/他唑巴坦治疗：CLEAR 登记结果。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-09-26 DOI: 10.1080/14787210.2024.2405930

George G Zhanel, Rita Dhami, Melanie Baxter, Maggie Wong, Yazdan Mirzanejad, Justin Kosar, Carlos Cervera, Neal Irfan, Sergio Borgia, Alex Serebryanskyy, Robert Ariano, Michel Savoie, Carlo Tascini, Andrew Walkty, James A Karlowsky

{"title":"Ceftolozane/Tazobactam treatment for patients with hospital-acquired and ventilatory-associated bacterial pneumonia in Canada in 2022-2024: results from the CLEAR registry.","authors":"George G Zhanel, Rita Dhami, Melanie Baxter, Maggie Wong, Yazdan Mirzanejad, Justin Kosar, Carlos Cervera, Neal Irfan, Sergio Borgia, Alex Serebryanskyy, Robert Ariano, Michel Savoie, Carlo Tascini, Andrew Walkty, James A Karlowsky","doi":"10.1080/14787210.2024.2405930","DOIUrl":"https://doi.org/10.1080/14787210.2024.2405930","url":null,"abstract":"Background: We report results from the national CLEAR (Canadian Leadership on Antimicrobial Real-Life Usage) registry on the usage of ceftolozane/tazobactam in Canada from 2022 to 2024.Research design and methods: The authors reviewed the final data using the national ethics approved CLEAR study. Thereafter, the literature is surveyed regarding the usage of ceftolozane/tazobactam to treat patients with HABP and VABP via PubMed (up to May 2024).Results: Ceftolozane/tazobactam was primarily used as directed therapy to treat HABP and VABP caused by Pseudomonas aeruginosa. It was primarily used alone, or in combination with another agent, to treat resistant and multidrug-resistant (MDR) P. aeruginosa infections. Despite primarily being used to treat severely ill patients in intensive care units, its use was associated with relatively high microbiological/clinical cure rates, along with an excellent safety profile. Several reports attest to the microbiological/clinical efficacy and safety of using ceftolozane/tazobactam to treat HABP and VABP.Conclusions: In Canada, ceftolozane/tazobactam is primarily used as directed therapy alone, or in combination, to treat MDR P. aeruginosa infections. Though mostly used to treat severely ill patients in the ICU, ceftolozane/tazobactam use in HABP and VABP is associated with relatively high microbiological/clinical cure rates and an excellent safety profile.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-8"},"PeriodicalIF":4.2,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of calcified cysticerci in the brain parenchyma: treating the dead parasite. 脑实质内钙化囊尾蚴的治疗：治疗死亡的寄生虫。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-09-26 DOI: 10.1080/14787210.2024.2409404

Oscar H Del Brutto

{"title":"Management of calcified cysticerci in the brain parenchyma: treating the dead parasite.","authors":"Oscar H Del Brutto","doi":"10.1080/14787210.2024.2409404","DOIUrl":"https://doi.org/10.1080/14787210.2024.2409404","url":null,"abstract":"Introduction: Calcifications are the end stage of many parenchymal brain cysticerci and may occur either spontaneously or as the result of treatment with cysticidal drugs. These lesions, traditionally considered inert and asymptomatic, have been associated with several complications that seem to be mostly related to brain damage and inflammation ensuing as the result of the exposure of the host's immune system to parasitic antigens trapped within calcifications.Areas covered: This review, based on the search of different electronic databases up to May 2024, focuses on the reported correlates and complications of calcified cysticerci (chronic headaches, seizures/epilepsy, hippocampal atrophy/sclerosis, gliomas), and the different interventions developed for their prevention and treatment. Common analgesics, non-steroidal anti-inflammatory drugs, corticosteroids, and antiseizure medications have been used with success but, with the exception of the latter, these drugs offer temporary relief of symptoms and support for their use is based on level 3 evidence.Expert opinion: Several strategies may reduce the severity of clinical consequences of calcified cysticerci. Probably, the most relevant intervention would be the prevention of their occurrence or reduction in their size. In this view, the use of bisphosphonates appears as a potential option that needs to be tested in humans.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-12"},"PeriodicalIF":4.2,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical pharmacokinetics of antimicrobials in critical care: a narrative review. 重症监护中抗菌药物的临床药代动力学：叙述性综述。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-09-24 DOI: 10.1080/14787210.2024.2406466

Ritika Kondel Bhandari, Rachna Rohilla, Nusrat Shafiq, Avaneesh Kumar Pandey, Samir Malhotra

{"title":"Clinical pharmacokinetics of antimicrobials in critical care: a narrative review.","authors":"Ritika Kondel Bhandari, Rachna Rohilla, Nusrat Shafiq, Avaneesh Kumar Pandey, Samir Malhotra","doi":"10.1080/14787210.2024.2406466","DOIUrl":"10.1080/14787210.2024.2406466","url":null,"abstract":"Introduction: The management of critically ill septic patients presents considerable challenges due to multifaceted physiological alterations. Rapid changes such as fluid shifts, hyperdynamic states, and altered renal clearance often require special attention for better clinical outcomes. Vital organ dysfunction, with or without MODS, often necessitates supportive management like RRT, ventilatory support, and ECMO. These interventions can significantly affect the PK/PD of administered antimicrobials, complicating effective treatment.Area covered: Patient-specific parameters such as age, weight, and comorbid illnesses (e.g. cystic fibrosis, burns, and immunocompromised states) are critical determinants of antimicrobial pharmacokinetics. Understanding PK/PD determinants is crucial for developing optimized dosing regimens that enhance therapeutic efficacy and minimize toxicity in critically ill patients.Expert opinion: Incorporating pharmacometrics approaches in dose optimization can significantly improve patient outcomes. This review focuses on the nuances of PK/PD for optimized antimicrobial dosing in critically ill septic patients, emphasizing the importance of individualized treatment plans to address the complex and dynamic needs of this patient population. The adoption of these advanced pharmacokinetic and pharmacodynamic principles into clinical practice is essential for advancing patient care and optimizing therapeutic outcomes in critically ill patients.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-14"},"PeriodicalIF":4.2,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Now that griseofulvin is not available, what to do with tinea capitis treatments? 现在没有了格列齐芬，该如何治疗头癣呢？

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-09-19 DOI: 10.1080/14787210.2024.2405936

Alexandro Bonifaz, Paola Lumbán-Ramírez, Roxana S García-Sotelo, Helena Vidaurri de la Cruz, Mirna Toledo-Bahena, Adriana Valencia-Herrera

{"title":"Now that griseofulvin is not available, what to do with tinea capitis treatments?","authors":"Alexandro Bonifaz, Paola Lumbán-Ramírez, Roxana S García-Sotelo, Helena Vidaurri de la Cruz, Mirna Toledo-Bahena, Adriana Valencia-Herrera","doi":"10.1080/14787210.2024.2405936","DOIUrl":"10.1080/14787210.2024.2405936","url":null,"abstract":"Introduction: Griseofulvin, discovered in 1939 and commercially available since 1959, was the first oral antifungal agent effective against dermatophytosis, particularly tinea capitis. Although it was eventually superseded by azole antifungals due to its long treatment duration and reliance on keratopoiesis, griseofulvin remains notable for its effectiveness and safety in treating tinea capitis, especially when caused by Microsporum canis. However, due to a decline in cases and commercial unavailability, alternative treatments are now required.Areas covered: The following topics regarding to other treatments were discussed: (I) The efficacy of alternative antifungal agents such as terbinafine, itraconazole, and fluconazole, in the treatment of tinea capitis. (II) The use and role of topical therapies. (III) Experience in the management of tinea capitis.Expert opinion: The usefulness of oral terbinafine as a replacement for griseofulvin in the treatment of tinea capitis and why it is the preferred drug in elderly patients was discussed. Challenges with Microsporum spp. and the use of fluconazole in pediatric patients were also analyzed. Support for the use of topical treatment as an adjunctive treatment for tinea capitis was highlighted.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-6"},"PeriodicalIF":4.2,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel agents in development for the treatment of resistant Gram-negative infections. 正在开发用于治疗耐药性革兰氏阴性菌感染的新型制剂。

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-09-18 DOI: 10.1080/14787210.2024.2407068

Matteo Bassetti,Barbara Larosa,Antonio Vena,Daniele Roberto Giacobbe

{"title":"Novel agents in development for the treatment of resistant Gram-negative infections.","authors":"Matteo Bassetti,Barbara Larosa,Antonio Vena,Daniele Roberto Giacobbe","doi":"10.1080/14787210.2024.2407068","DOIUrl":"https://doi.org/10.1080/14787210.2024.2407068","url":null,"abstract":"INTRODUCTIONSeveral novel agents are in advanced stages of clinical development, potentially expanding our treatment options against third- and fourth-generation cephalosporin-resistant and carbapenem-resistant Gram-negative bacteria (GNB), including those pathogens for which the current number of effective treatments is limited.AREAS COVEREDThis review focuses on agents that have completed or ongoing phase-3 studies. A PubMed search was conducted up to 31 May 2024.EXPERT OPINIONNovel agents in late-stage clinical development belong to the β-lactam or β-lactam/β-lactamase inhibitor combinations class and display variable antimicrobial activity depending on the specific β-lactamases expressed by GNB, particularly carbapenemases. While many of these novel agents demonstrate in vitro activity against carbapenem-resistant GNB, their efficacy has mainly been evaluated in phase-3 randomized controlled trials (RCT) for infections caused by carbapenem-susceptible GNB. Although evidence from real-world observational studies is generally less robust than that from RCT, it could be crucial for updating clinical guidelines on treating carbapenem-resistant GNB with these new agents in the absence of dedicated RCT.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":"45 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142262093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Diagnosing fungal infections in clinical practice: a narrative review. 临床实践中的真菌感染诊断：综述。

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-09-13 DOI: 10.1080/14787210.2024.2403017

Sarah Sedik,Stella Wolfgruber,Martin Hoenigl,Lisa Kriegl

{"title":"Diagnosing fungal infections in clinical practice: a narrative review.","authors":"Sarah Sedik,Stella Wolfgruber,Martin Hoenigl,Lisa Kriegl","doi":"10.1080/14787210.2024.2403017","DOIUrl":"https://doi.org/10.1080/14787210.2024.2403017","url":null,"abstract":"BACKGROUNDInvasive fungal infections (IFI) present a major medical challenge, with an estimated 6.5 million cases annually, resulting in 3.8 million deaths. Pathogens such as Aspergillus spp. Candida spp. Mucorales spp. Cryptococcus spp. and other fungi species contribute to these infections, posing risks to immunocompromised individuals. Early and accurate diagnosis is crucial for effective treatment and better patient outcomes.AREAS COVEREDThis narrative review provides an overview of the current methods and challenges associated with diagnosing fungal diseases including invasive aspergillosis, invasive candidiasis as well as rare and endemic fungal infections. Various diagnostic techniques, including microscopy, culture, molecular diagnostics, and serological tests, are reviewed, highlighting their respective advantages and limitations and role in clinical guidelines. To illustrate, the need for improved diagnostic strategies to overcome existing challenges, such as the low sensitivity and specificity of current tests and the time-consuming nature of traditional culture-based methods, is addressed.EXPERT OPINIONCurrent advancements in fungal infection diagnostics have significant implications for healthcare outcomes. Improved strategies like molecular testing and antigen detection promise early detection of fungal pathogens, enhancing patient management. Challenges include global access to advanced technologies and the need for standardized, user-friendly point-of-care diagnostics to improve diagnosis of fungal infections globally.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":"19 1","pages":""},"PeriodicalIF":5.7,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142262038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunomodulatory markers and therapies for the management of infant respiratory syncytial virus infection 治疗婴儿呼吸道合胞病毒感染的免疫调节标记物和疗法

IF 5.7 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2024-09-13 DOI: 10.1080/14787210.2024.2403147

Ricardo A. Loaiza, Mónica A. Farías, Catalina A. Andrade, Mario A. Ramírez, Linmar Rodriguez-Guilarte, José T. Muñóz, Pablo A. González, Susan M. Bueno, Alexis M. Kalergis

引用次数: 0